Related Experiment Videos
[Chronic inflammatory demyelinating polyradiculoneuropathy. Study of 18 cases]
L C Calia1, A S Oliveira, A A Gabbai
1Universidade Federal de São Paulo, Escola Paulista de Medicina (UNIFESP-EPM), Brasil.
Arquivos De Neuro-Psiquiatria
|June 18, 1998
Summary
This study followed 18 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), finding that prednisone treatment led to functional improvement in most cases. Azathioprine was effective for non-responders, with some achieving remission.
Area of Science:
- Neurology
- Immunology
- Clinical Medicine
Context:
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disorder affecting peripheral nerves.
- Idiopathic CIDP presents with progressive or relapsing motor and sensory dysfunction.
- Understanding the clinical course and treatment response is crucial for patient management.
Purpose:
- To describe the clinical characteristics, disease evolution, and therapeutic responses in a cohort of 18 patients with idiopathic CIDP.
- To evaluate the efficacy of prednisone and azathioprine in managing CIDP symptoms.
- To analyze electrophysiological and histopathological findings in relation to treatment outcomes.
Summary:
- 18 idiopathic CIDP patients were prospectively studied for 4-127 months, noting male predominance and a mean age of onset.
- All patients exhibited motor/sensory deficits and demyelination; 88.9% had elevated CSF protein. Prednisone was effective in 72.2%, with azathioprine used for non-responders.
- Functional improvement was observed in 88.9% of patients, with two achieving remission after medication withdrawal.
Impact:
- This study highlights the effectiveness of prednisone as a first-line treatment for idiopathic CIDP, with azathioprine as a viable alternative.
- Findings provide valuable insights into the long-term management and prognosis of CIDP patients.
- The results support current therapeutic strategies and may inform future clinical guidelines for CIDP management.